ArticleBlood neoplasia2025
Olfactory receptors as tumor suppressors in cutaneous T-cell lymphoma via p38γ pathway modulation.
Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Our previous observations revealed significant overexpression of p38γ in cutaneous T-cell lymphoma (CTCL), small molecule inhibitors of the lipid-binding site of p38γ, CSH18 and CSH71 exhibited strong cytotoxicity against CTCL cells while sparing healthy cells. We report here that both compounds significantly enhanced the activity of the olfactory transduction pathway, and each induces a unique combination of olfactory receptors (ORs). CSH71 increased gene expression of OR4N5, an OR that functions as a tumor suppressor CTCL Hut78 cells; its suppression is associated with accelerated cell proliferation. The study elucidates the potential mechanism wherein the targeting of the p38γ lipid-binding site affects the alternative p38 phosphorylation via ζ-chain-associated protein kinase 70, thereby T-cell receptor (TCR) activation. The expression of OR4N5 and CD3E is reduced in CTCL; scattered aberrant CD3Es are in the cytosol and surrounds the nuclear envelope. Membranous OR4N5 no longer interacts with CD3E in CTCL cells, which sets TCR signaling transduction on the loose via depending on other mechanisms such as the DLGH1-p38γ-nuclear factor of activated T-cells 1 axis. Analysis of public data sets shows that most ORs are significantly downregulated in cancer, suggesting their grassroot tumor suppressors role when a network emerged as they teamed together against cancer.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.